Andrew Wilcock on Muck Rack

Andrew Wilcock

As seen in: SAGE Publishing, Thorax, JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association, JAMA Cardiology, JAMA Health Forum Conversations, Health Affairs, European Respiratory Journal, American Journal of Preventive Medicine and
Consultant in Palliative Medicine and Honorary Associate Professor, Editor-in-chief Palliative Care Formulary
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Factors Underlying Reduced Hospitalizations for Myocardial Infarction During the COVID-19 Pandemic

|
By Andrew Wilcock, Robert W. Yeh, Lee H. Schwamm, Ateev Mehrotra
| JAMA Cardiology
Key Points Question What underlies the sustained reduction in acute myocardial infarction (AMI) hospital encounters that began during the COVID-19 pandemic?
Open in Who Shared Issue with article?

Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population

|
By Andrew Wilcock, Stephen Kissler, Ateev Mehrotra, Brian McGarry
| JAMA Health Forum Conversations
Key Points Question How did access to outpatient COVID-19 therapy vary across patients in the Medicare program in 2022, and what clinical factors explain these differences? Findings In this cross-sectional study of patients enrolled in Medicare in 2022, those at the highest risk for severe COVID-19 infection received COVID-19 therapy less often than those with the least risk.
Open in Who Shared Issue with article?

Treatment of SARS-CoV-2 Infection in US Nursing Homes-Reply

|
By Brian McGarry, Benjamin D. Sommers, Michael Barnett, Andrew Wilcock
| JAMA: Journal of the American Medical Association Verified
Treatment of SARS-CoV-2 Infection in US Nursing Homes—Reply In Reply Dr Bergman highlights a number of important potential barriers to COVID-19 antiviral treatment use in nursing homes, including rapidly evolving guidelines concerning the use of monoclonal antibodies, insufficient supply of recommended monoclonal antibodies, and high staffing needs to administer monoclonal antibodies intravenously.
Open in Who Shared Issue with article?
See all 28 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified